Fighting fire with fire: Rekindling the bevacizumab debate

New England Journal of Medicine

Volumn 366, Issue 4, 2012, Pages 374-375

  Montero, Alberto J ^a   Vogel, Charles ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TUMOR MARKER;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; EDITORIAL; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR VASCULARIZATION;

EID: 84856263234     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1113368     Document Type: Editorial

References (10)

1. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366:310-20.
2. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012;366:299-309.
3. Gray R, Bhattacharya S, Bowden C, Miller K, Cornis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27:4966-72.
4. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
5. Montero AJ, Escobar M, Lopes G, Glück S, Vogel C. Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep 2011 October 20 (Epub ahead of print).
6. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12:933-80.
7. Aogi K, Masuda N, Ohno S, et al. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 2011;129:829-38.
8. Martin M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011;12:369-76. [Erratum, Lancet Oncol 2011;12:722.]
9. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
10. Brufsky A, Valero V, Tiangco B, et al. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): analysis of RIBBON-2. In: Program and abstracts of American Society of Clinical Oncology Annual Meeting, Chicago, June 3-7, 2011. abstract.